Immunovant 

Price & Volume

Track all markets on TradingView

Stats

See more
52W Range
$17.01-$34.47
Market Cap
$3.3B
Shares Short
14M

Financials

See more
Revenue (12 Mos)
$0
Revenue Growth (YoY)
0%
Gross Profit (12 Mos)
$0
Diluted EPS
-$2.62

News

See more

Yahoo Finance • 5 days ago

Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Yahoo Finance • 5 days ago

Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Yahoo Finance • 6 days ago

Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

Yahoo Finance • 6 days ago

Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

About

CEO
Dr. Peter Salzmann M.B.A., M.D.
Address
320 West 37th Street, New York, NY, United States, 10018
Sector
Healthcare
Industry
Biotechnology
Full-Time Employees
207